Anti-PD-1 plus anti-HER2 and chemotherapy showed superior and durable clinical benefit in a patient with advanced salivary duct carcinoma

Affiliations

• ¹ Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
• ² Jiangsu Simcere Diagnostics Co., Ltd, The State Key Laboratory of Translational Medicine and Innovative Drug Development, Nanjing 210018, China.
• ³ Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. Electronic address: [email protected].
• ⁴ Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. Electronic address: [email protected].